May 19, 2011
VBL Therapeutics Presents Preclinical Data for VB-111 at the 14th Annual ASGCT Meeting

FOR IMMEDIATE RELEASE 

 

Media Contact:

Dan Budwick, Pure Communications

973-271-6085

 

 

VBL Therapeutics Presents Preclinical Data for VB-111 at 
the 14th Annual ASGCT Meeting

 

Data demonstrate synergistic additive effects of VB-111, a dual action anti-angiogenic and vascular disruptive agent, in combination with chemotherapy 
in preclinical model of metastatic lung cancer

 

TEL AVIV, Israel and SEATTLE, May 19, 2011 – VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111’s potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments. The company will present data demonstrating this synergistic effect in an in vivo preclinical model of metastatic lung cancer at 4:40 p.m. PT today at the 14th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) at the Washington State Convention Center in Seattle.

 

VB-111 is the first targeted, dual-action, anti-angiogenic and Vascular Disruptive Agent (VDA) to use VTS, the company’s proprietary platform technology, for cancer therapy. VB-111 is an IV-administered VDA that works in a manner akin to a “biological knife” to destroy tumor vasculature, thus cutting off the blood vessels feeding the tumor. VB-111 is currently being investigated in Phase 2 clinical studies in thyroid cancer and in glioblastoma.

 

“We are pleased to present these compelling data at ASGCT,” said Eyal Breitbart, Ph.D., vice president of research at VBL. “These studies continue to demonstrate VB-111’s promise as a targeted cancer treatment and illustrate its potential to work synergistically in combination with conventional chemotherapy treatments to provide a more effective treatment regimen for cancer patients. Importantly, VB-111’s unique mechanism of action targets tumors with precision and specificity, causing no significant damage to the normal non-cancerous tissue or vasculatures in the body.”

 

The studies demonstrated that VB-111 as a combined therapy with the chemotherapy doxorubicin in a Lewis Lung metastasis model showed additive effect compared to treatment with VB-111 alone. Additionally, additive effect was also seen after treatment with a lower dose of VB-111 in combination with paclitaxel compared to treatment with either VB-111 or paclitaxel alone. No toxicity was observed as a result of these combined therapies, and the treated groups were found to have normal growth pathology with no lesions or evidence of metastasis.

 

 

About VB-111

VB-111 is a dual-action, anti-angiogenic and Vascular Disruptive Agent (VDA) that utilizes VTS, VBL’s proprietary platform technology for cancer therapy. VB-111 is an intravenously administered VDA that works in a manner akin to a “biological knife” to destroy tumor vasculature, thus cutting off the blood vessels feeding the tumor.

 

Preclinical pharmacological and toxicology studies of VB-111 showed tissue specificity for the tumor tissue, no significant damage to normal non-cancerous tissues or to the normal vasculatures in the body, and a more than 90 percent reduction in metastatic lung cancer model with one injection, as well as similar efficacy in other tumor models. A Phase 1 “all-comers” study of VB-111 in 33 patients with advanced metastatic cancer demonstrated antitumor activity and no effects on liver function or major changes in complete blood count. VB-111 is currently in Phase 2 clinical trials for thyroid cancer and glioblastoma.

 

About VBL Therapeutics

VBL Therapeutics is an innovative, clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer. VBL has pioneered the Lecinoxoid class of oral anti-inflammatory agents. VB-201 is the company’s lead candidate from this program, currently in Phase 2 clinical development in patients with psoriasis and patients with elevated hsCRP levels. In addition, VBL has a proprietary Vascular Targeting System (VTS) technology platform that has yielded VB-111, a dual-action, anti-angiogenic and vascular disruptive agent (VDA) for cancer, which is currently in Phase 2 clinical trials for thyroid cancer and glioblastoma. The company is based in Tel Aviv, Israel. VBL has 70 granted patents and more than 110 patents pending. For more information on the company, please visitwww.vblrx.com.